Latest News and Press Releases

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of...

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver...

-Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023- -Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of...

- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in...

SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...

SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...

-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver...

SAN FRANCISCO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...

   - Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 - - ENTRIGUE...

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...